Ajinomoto Bio-Pharma Services US

Ajinomoto Althea, Inc. is a Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceutical services, focusing on large and small molecule manufacturing and drug product development to meet industry demands. Ajinomoto Althea, Inc. operates as a CDMO offering services in biopharmaceutical manufacturing.

Founded in 1998, the company is headquartered in San Diego, US. The firm's founder has a background in the biopharmaceutical industry, contributing to its establishment. Ajinomoto Althea has not reported any significant pivots in business strategy or operations since its inception. The company has executed a total of 1 deal, with its most recent deal occurring on April 24, 2025.

Aji Bio-Pharma specializes in providing comprehensive Contract Development and Manufacturing Organization (CDMO) services, with a focus on large molecule manufacturing, small molecule manufacturing, aseptic fill-finish processes, and drug product manufacturing. Their offerings encompass a wide range of services designed to support the biopharmaceutical industry, including the development and production of highly potent compounds and antibody-drug conjugates (ADCs). Aji Bio-Pharma targets various end users, including pharmaceuticals and biotechnology companies engaged in clinical development and commercialization of therapeutic products, serving a global client base with a particular focus on North America, Europe, and Asia. Aji Bio-Pharma generates revenue through strategic partnerships and B2B transactions with pharmaceutical and biotech firms.

The company typically engages clients on a project basis, offering tailored solutions that include both development and manufacturing services. Revenue is derived from contracts that may include fixed-price agreements or milestone-based payments contingent upon project progress and the successful delivery of services. Aji Bio-Pharma’s flagship offerings, particularly in large molecule and small molecule manufacturing, play a critical role in their revenue structure, attracting clients requiring high compliance with cGMP standards and quality assurance. The firm maintains a robust pipeline of transactions, reflecting a commitment to quality and innovation that resonates with its client base across various geographical markets.

In April 2025, PCI Pharma Services, a portfolio company of Partners Group and Kohlberg & Company, agreed to fully acquire Ajinomoto Bio-Pharma Services US. The financial terms of the transaction were not disclosed. This acquisition will enhance PCI Pharma Services' product and service offerings. The company is expected to utilize this acquisition to expand its reach and enhance its capabilities within the biopharmaceutical sector.